HEMOSTASIS PROFILE AND CLINICAL OUTCOME OF ACUTE ISCHEMIC STROKE PATIENTS TREATED WITH ORAL LUMBROKINASE DLBS1033: A COMPARATIVE STUDY VERSUS ASPIRIN AND CLOPIDOGREL

  • Ismail Setyopranoto Department of Neurology, Faculty of Medicine, University of Gadjah Mada / dr. Sardjito Hospital, Yogyakarta, Indonesia
  • Samekto Wibowo Department of Neurology, Faculty of Medicine, University of Gadjah Mada / dr. Sardjito Hospital, Yogyakarta, Indonesia.
  • Raymond R. Tjandrawinata Dexa Laboratories of Biomolecular Sciences (DLBS)

Abstract

Objectives: This clinical study was conducted to determine the hemostasis profile and clinical outcome of acute ischemic stroke patients treated with
DLBS1033 in comparison with aspirin or clopidogrel. DLBS1033 is a proprietary bioactive protein fraction derived from the earthworms (Lumbricus
rubellus) that possesses both fibrinolytic and antithrombotic properties.
Methods: This was a 3-arm, parallel, randomized, controlled, open-label, blinded-evaluation study involving 126 acute ischemic stroke patients. Each
subject received any of the following study medication within 96 hrs after the stroke onset: Aspirin 80 mg daily (Group 1), or clopidogrel 75 mg dail(Group 2), DLBS1033 490 mg 3 times daily (Group 3), for 90 days. Hemostasis parameters evaluated were prothrombin time (PT), activated partial
thromboplastin time (aPTT), and international normalized ratio (INR), while the clinical outcomes were measured using Gadjah Mada Stroke Scale
(SSGM) and Barthel index (BI).
Results: Baseline characteristics, including the hemostasis and clinical profiles, were comparable between groups. At the end of the study, PT, aPTTand INR values were not significantly different between groups, which were all within the normal ranges. There was a significant improvement of BI
as well as SSGM from baseline in each group. The improvement size of BI was found similar between groups (p=0.098). However, a significantly better
improvement of SSGM was observed in those received DLBS1033 (6.98±4.90; p=0.001 vs. aspirin [3.74±3.66], p=0.006 vs. clopidogrel [4.26±4.21]).
Conclusion: It was concluded that DLBS1033 provided a safe hemostasis profile (PT, aPTT, and INR) comparable to that of aspirin or clopidogrel in
ischemic stroke patients. Treatment with DLBS1033 improved clinical outcomes indicated by the BI and SSGM, and the improvement size of SSGM was
even better than that of aspirin or clopidogrel treatment.
Keywords: Acute ischemic stroke, Barthel index, DLBS1033, Hemostasis, Gadjah Mada Stroke Scale, Oral lumbrokinase.

References

REFERENCES
1. Schulman SP, Fessler HE. Management of acute coronary syndromes.
Am J Respir Crit Care Med 2001;164(6):917-22.
2. Singh V. Critical care assessment and management of acute ischemic
stroke. J Vasc Interv Radiol 2004;15:S21-7.
3. Jauch EC, Saver JL, Adams HP, Bruno A, Connors JJ, Demaerschalk BM,
et al. The American Heart Association Stroke Council, Council on
Cardiovascular Nursing, Council on Peripheral Vascular Disease, and
Council on Clinical Cardiology. Guidelines for the early management
of patients with acute ischemic stroke: A guideline for healthcare
professionals from the American Heart Association/American Stroke
Association. Stroke 2013;44(1):1-78.
4. Bansal S, Sangha KS, Khatri P. Drug treatment of acute ischemic
stroke. Am J Cardiovasc Drugs 2013;13(13):57-69.
5. Simes J, Becattini C, Agnelli G, Eikelboom JW, Kirby AC, Mister R,
et al. Aspirin for the prevention of recurrent venous thromboembolism:
The INSPIRE collaboration. Circulation 2014;130(9038):1062-71.
6. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel
versus aspirin in patients at risk of ischaemic events (CAPRIE).
CAPRIE Steering Committee. Lancet 1996;348(10):1329-39.
7. Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S,
Matsuoka K, et al. Cilostazol for prevention of secondary stroke
(CSPS 2): An aspirin-controlled, double-blind, randomised noninferiority
trial. Lancet Neurol 2010;9:959-68.
8. Ezekowitz MD, Connolly S, Parekh A, Reilly PA, Varrone J, Wang S,
et al. Rationale and design of RE-LY: Randomized evaluation of longterm
anticoagulant
therapy,
warfarin, compared with dabigatran. Am

Heart
J 2009;157(5):805-10, 810.e1-2.
9. Caplan LR. Basic pathology, treatment. In: Caplan’s Stroke: A Clinical
Approach. 4
ed., Vol. 5. Philadelphia: Saunders Elsevier; 2009. p. 148.
10. Warlow C, van Gijn J, Dennis M, Wardlaw J, Bamford J, Hankey G,
th
et al. Specific treatments for acute ischemic stroke. In: Stroke: Practical
Management. 3
ed., Vol. 12. Massachussetts: Blackwell Publishing;
2008. p. 649-50.
rd
191
Asian J Pharm Clin Res, Vol 9, Issue 1, 2016, 186-192
Setyopranoto et al.
11. Musallam KM, Charafeddine K, Bitar A, Khoury M, Assaad S,
Beresian J, et al. Resistance to aspirin and clopidogrel therapy. Int J
Lab Hematol 2011;33(1):1-18.
12. Cuisset T, Cayla G. Aspirin and clopidogrel resistance: Should we
worry about? Minerva Med 2010;101(1):35-47.
13. Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: An
emerging clinical entity. Eur Heart J 2006;27(6):647-54.
14. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramírez C, Sabaté M,
Jimenez-Quevedo P, et al. Platelet function profiles in patients with
type 2 diabetes and coronary artery disease on combined aspirin and
clopidogrel treatment. Diabetes 2005;54(8):2430-5.
15. Mihara H, Sumi H, Akazawa K, Yoneta T, Mizumoto H. Fibrinolytic
enzyme extracted from the earthworm. Thromb Haemost 1983;50:258-63.
16. Mihara H, Sumi H, Yoneta T, Mizumoto H, Ikeda R, Seiki M, et al.
A novel fibrinolytic enzyme extracted from the earthworm, Lumbricus
rubellus. Jpn J Physiol 1991;41:461-72.
17. Cho IH, Choi ES, Lim HG, Lee HH. Purification and characterization
of six fibrinolytic serine-proteases from earthworm Lumbricus rubellus.
J Biochem Mol Biol 2004;37(2):199-205.
18. Nakajima N, Mihara H, Sumi H. Characterization of potent fibrinolytic
enzymes in earthworm, Lumbricus rubellus. Biosci Biotechnol
Biochem 1993;57(10):1726-30.
19. Ji H, Wang L, Bi H, Sun L, Cai B, Wang Y, Zhao J, Du Z. Mechanisms
of lumbrokinase in protection of cerebral ischemia. Eur J Pharmacol
2008;590(1-3):281-9.
20. Zhang HY. Clinical evaluation of treating acute ischemic cerebrovascular
disease with lumbrokinase. Cap Med 2000;7(3):45-6.
21. Trisina J, Sunardi F, Suhartono MT, Tjandrawinata RR. DLBS1033, a
protein extract from Lumbricus rubellus, possesses antithrombotic and
thrombolytic activities. J Biomed Biotechnol 2011;2011:519652.
22. Sukandar EY, Anggadireja K, Sigit JI, Adnyana IK, Tjandrawinata RR.
Toxicity studies of a bioactive protein with antithrombotic–thrombolytic
activity, DLBS1033. Drug Chem Toxicol 2014;37(1):8-16.
23. Yunaidi DA, Putri RS, Astoro NW. A Randomized, Double-Blind,
Placeboc Ontrolled, Cross-Over, and Fixed-Dose Study to Evaluate
the Safety and Efficacy of DLBS1033 in Healthy Subjects [Report].
Jakarta: PT Equilab International; 2011.
24. Gayatri A. The effect of DLBS1033 on Fibrinolytic Parameters in Healthy
Volunteers [Thesis, in Bahasa]. Jakarta: University of Indonesia; 2012.
25. Setiawati E, Yunaidi DA, Handayani LR, Santoso ID, Setiawati A,
Tjandrawinata RR. Bioequivalence study of two clopidogrel filmcoated
tablet
formulations
in healthy volunteers.
Arzneimittelforschung

2011;61(12):681-4.
26. Tjandrawinata RR, Trisina J, Rahayu P, Prasetya LA, Hanafiah A,
Rachmawati H. Bioactive protein fraction DLBS1033 containing
lumbrokinase isolated from Lumbricus rubellus: Ex vivo, in vivo, and
pharmaceutic studies. Drug Des Devel Ther 2014;8:1585-93.
27. Shah S, Vanclay F, Cooper B. Improving the sensitivity of the Barthel
index for stroke rehabilitation. J Clin Epidemiol 1989;42(8):703-9.
28. Barer DH, Murphy JJ. Scaling the barthel: A 10-point hierarchical
version of the activities of daily living index for use with stroke patients.
Clin Rehabil 1993;7(4):271-7.
29. Sainsbury A, Seebass G, Bansal A, Young JB. Reliability of the Barthel
index when used with older people. Age Ageing 2005;34(3):228-32.
30. Duffy L, Gajree S, Langhorne P, Stott DJ, Quinn TJ. Reliability (interrater
agreement) of the Barthel Index for assessment of stroke survivors:
Systematic
review and meta-analysis. Stroke 2013;44(2):462-8.
31. Sinoff G, Ore L. The Barthel activities of daily living index: Selfreporting
versus
actual performance
in
the old-old (> or = 75
years).

J
Am
Geriatr Soc 1997;45(7):832-6.
32. Goodnight SH, Hathaway WE. Disorder of Haemostatis and Thrombosis
a Clinical Guide. 2
ed. New York: McGraw-Hill; 2001. p. 23.
33. Root RK, Jacobs R. Septicemia and septic shock. In: Wilson JD,
nd
Braunwald E, Isselbacker KJ, Fauci AS, editors. Harison’s Principles of
Internal Medicine. 16
ed. New York: McGraw-Hill; 2005. p. 502-7.
34. Lamsudin R. Reliability of Gadjah Mada Stroke Scale (SSGM) in Stroke
th
Patients. Malang, Bahasa: Proceedings of the Annual Conference of the
Association of Indonesian Neurologists; 1998.
35. Tamura T, Sakaeda T, Kadoyama K, Okuno Y. Aspirin- and clopidogrelassociated
bleeding
complications:
Data
mining of
the public
version

of
the
FDA
adverse
event
reporting
system,
AERS.
Int J
Med Sci

2012;9(6):441-6.
36. Hwang HW, Kong JH, Yu DW, Kim WT, Kim HS, Lee CI. A patient
with acquired hemophilia A induced by clopidogrel. Korean J Hematol
2012;47(1):80-2.
37. Granger CV, Dewis LS, Peters NC, Sherwood CC, Barrett JE. Stroke
rehabilitation: Analysis of repeated Barthel index measures. Arch Phys
Med Rehabil 1979;60(1):14-7.
38. Kay R, Wong KS, Perez G, Woo J. Dichotomizing stroke outcomes
based on self-reported dependency. Neurology 1997;49(6):1694-6.
39. Dennis M, Wellwood I, Warlow C. Are simple questions a valid
measure of outcome after stroke? Cerebrovasc Dis. 1997;7:22-7.
40. Sulter G, Steen C, De Keyser J. Use of the Barthel index and modified
Rankin scale in acute stroke trials. Stroke 1999;30(8):1538-41.
41. Kurnia F, Tjandrawinata RR. Bioactive protein fraction DLBS1033
exerts its positive pleiotropic effects in the vascular cells via down
regulation of gene expression. Medicinus 2011;24(1):18-24.
42. Johnston KC, Wagner DP, Haley EC Jr, Connors AF Jr, RANTTAS
Investigators. Randomized trial of tirilazad mesylate in acute stroke.
Combined clinical and imaging information as an early stroke outcome
measure. Stroke 2002;33(2):466-72.
43. Davis JP, Wong AA, Schluter PJ, Henderson RD, O’Sullivan JD,
Read SJ. Impact of premorbid undernutrition on outcome in stroke
patients. Stroke 2004;35:1930-4.
44. Rudd AG, Hoffman A, Irwin P, Lowe D, Pearson MG. Stroke unit care
and outcome: Results from the 2001 National sentinel audit of stroke
(England, wales, and Northern Ireland). Stroke 2005;36(1):103-6.
45. Greer DM, Funk SE, Reaven NL, Ouzounelli M, Uman GC. Impact
of fever on outcome in patients with stroke and neurologic injury:
A comprehensive meta-analysis. Stroke 2008;39:3029-35.
46. Yong M, Kaste M. Dynamic of hyperglycemia as a predictor of stroke
outcome in the ECASS-II trial. Stroke 2008;39:2749-55.
47. Appelros P, Stegmayr B, Terént A. A review on sex differences in stroke
treatment and outcome. Acta Neurol Scand 2010;121:359-69.
Statistics
439 Views | 376 Downloads
How to Cite
Setyopranoto, I., S. Wibowo, and R. R. Tjandrawinata. “HEMOSTASIS PROFILE AND CLINICAL OUTCOME OF ACUTE ISCHEMIC STROKE PATIENTS TREATED WITH ORAL LUMBROKINASE DLBS1033: A COMPARATIVE STUDY VERSUS ASPIRIN AND CLOPIDOGREL”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 9, no. 1, Jan. 2016, pp. 186-92, https://innovareacademics.in/journals/index.php/ajpcr/article/view/8553.
Section
Original Article(s)